Eli Lilly agreed to acquire Ventyx Biosciences for $14.00 per share in an all-cash transaction valued at approximately $1.2 billion, a ~62% premium to the 30-day VWAP. The acquisition adds Ventyx's oral NLRP3 inhibitor franchise (VTX2735 in Phase 2 for recurrent pericarditis; VTX3232 CNS-penetrant for Parkinson's and cardiometabolic disease) plus tamuzimod (VTX002) S1P1R modulator and VTX958 TYK2 inhibitor for IBD. Deal follows positive Ventyx Phase 2 readouts in Parkinson's and cardiovascular biomarkers in late 2025. UPDATE (2026-03-04): The merger closed on March 4, 2026 at $14.00/share in cash (RYLS Merger Corporation merged into Ventyx, now a wholly owned Lilly subsidiary); Ventyx (Nasdaq: VTYX) was delisted from Nasdaq. (SEC Form 8-K, Ventyx Biosciences.)
MechanismNLRP3 inflammasome inhibition; also S1P1R modulator (tamuzimod/VTX002) and TYK2 inhibitor (VTX958) across IBD; CNS-penetrant NLRP3 (VTX3232) for Parkinson's/cardiometabolic